/ /

  • linkedin
  • Increase Font
  • Sharebar

    Selexipag Delays PAH Progression in Patients with Connective Tissue Disease

    Pulmonary arterial hypertension (PAH) is a dangerous complication of connective tissue disease (CTD), eg, systemic sclerosis, systemic lupus erythematosus, and has been historically difficult to treat. Recent studies suggest that treatment regimens that combine PAH therapies may be more effective in this population, but the studies are few. The current study analyzed a subgroup of patients with PAH-CTD enrolled in the GRIPHON trial (selective IP prostacyclin receptor agonist selexipag) to assess the impact of selexipag on PAH progression across CTD types. The study and results are summarized in this short slide show. Please click "2" below for first slide.

     

    References

    1. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–2533.

    2. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50. pii: 1602493. doi: 10.1183/13993003.02493-2016

     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available